17:59 , Aug 3, 2018 |  BC Week In Review  |  Company News

China Medical gains Chinese product rights in trio of deals

China Medical System Holdings Ltd. (HKSE:867) announced a series of deals in July under which it gained rights to several products in China, including Hong Kong, Macao and Taiwan. China Medical obtained exclusive rights from...
21:32 , Nov 18, 2016 |  BC Week In Review  |  Company News

Acticor, Mediolanum deal

Acticor and Mediolanum partnered to develop Acticor’s acute ischemic stroke candidate ACT017 . Mediolanum will co-own the results of the collaboration and acquire marketing rights in two undisclosed European countries. Acticor received an undisclosed upfront...
08:00 , Feb 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) Glycoprotein VI platelet (GP6; GPVI) In vitro and mouse studies suggest that antagonizing the GPVI receptor could help treat RA. In...
08:00 , Feb 25, 2010 |  BC Innovations  |  Targets & Mechanisms

Targeting platelets in RA

Harvard Medical School researchers have shown that platelets can contribute to inflammatory arthritis and have identified a collagen receptor on these cells that could be a target for treating RA. 1 But inhibiting the collagen...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Protein tyrosine phosphatase, receptor type, J (PTPRTJ; CD148); glycoprotein VI (platelet) (GP6; GPVI) A study in mice suggests that...
07:00 , Apr 10, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Deep vein thrombosis (DVT) Cytochrome P450, family 4, subfamily V, polypeptide 2 (CYP4V2) A genome-wide association analysis using three large...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Company News

Millennium, Trigen Holdings AG deal

Trigen received exclusive worldwide rights to develop and commercialize MLNM's IP covering glycoprotein VI ( GPVI ), a platelet collagen receptor involved in thrombosis. Trigen expects to complete Phase I testing of PR-15 to treat...
08:00 , Jan 29, 2007 |  BioCentury  |  Tools & Techniques

Little vascular plasters

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side...
08:00 , Jan 29, 2007 |  BioCentury  |  Tools & Techniques

The platelet plug

The platelet plug The platelet plugTrigen is looking to develop a novel anti-platelet approach by targeting an early step in the blood clot cascade, which limits blood loss after vascular injury. [1] The formation of...